March 25, 2019
JCR Pharmaceuticals said on March 22 that it has filed an application in Japan for its regenerative medicine product Temcell HS Inj., allogeneic bone marrow-derived mesenchymal stem cells, for an additional indication of epidermolysis bullosa via subcutaneous injection. Epidermolysis bullosa...read more